公开(公告)号：US20230358750A1

公开(公告)日：2023-11-09

申请号：US18352183

申请日：2023-07-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Anika Mang ,  Thomas Muley ,  Vinzent Rolny ,  Birgit Wehnl

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N2333/4742 ,  G01N2333/4725 ,  G01N2333/70596

Abstract: The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.

公开(公告)号：US20230305010A1

公开(公告)日：2023-09-28

申请号：US18309985

申请日：2023-05-01

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Anika Mang ,  David Morgenstern ,  Vinzent Rolny ,  Magdalena Swiatek-De Lange

IPC: G01N33/574

CPC classification number: G01N33/57438 ,  G01N2333/8146 ,  G01N2333/96494 ,  G01N2470/04 ,  G01N2800/50 ,  G01N2800/08

Abstract: The present invention relates to an in vitro method for assessing cholangiocarcinoma in a patient sample, comprising the steps of: a) determining the level of tissue inhibitor of metalloproteinase-1 (TIMP1) in the patient sample, wherein the patient sample is selected from a group consisting of serum, plasma and whole blood sample from an individual, b) comparing the level of TIMP1 determined in step (a) with a reference level of TIMP1, and c) assessing cholangiocarcinoma in the patient sample by comparing the level determined in step (a) to the reference level of TIMP1, wherein an increased level of TIMP1 compared to the reference level of TIMP1 is indicative for cholangiocarcinoma in the patient sample. Further, the present invention relates to an in vitro method for assessing cholangiocarcinoma comprising TIMP1 and MMP2, the use of TIMP1 and optionally MMP2 in the in vitro assessment of CCA, and a kit for performing the said methods.